Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Piper Jaffray Downgrades Elan

Piper Jaffray downgrades Elan Corp. (ELN).

Analyst Deborah Knobelman says she is downgrading Elan to market perform from outperform.

She believes the newly diagnosed case of PML (progressive ultifocal leukoencephalopathy) in a patient on Tysabri monotherapy adds a new level of risk to the possibility of Tysabri ever returning to market. She notes this is the third reported case of PML in a patient on Tysabri monotherapy.

Knobleman says she no longer feels comfortable recommending Elan shares, even for the most risk-tolerant investor. She maintains her earnings assumptions for Elan, as she had previously removed Tysabri from her model.

blog comments powered by Disqus